From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.

Inojosa H, Masanneck L, Akgün K, Hagler R, Meuth SG, Otto C, Schindler P, Schulze-Bosse K, Kuhle J, Benkert P, Ruprecht K, Pawlitzki M, Ziemssen T.

Open source

DOI: 10.1007/s00415-026-13986-9
Published: 2026-07-10
Container: J Neurol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00415-026-13986-9,
  title = {From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.},
  author = {Inojosa H and  Masanneck L and  Akgün K and  Hagler R and  Meuth SG and  Otto C and  Schindler P and  Schulze-Bosse K and  Kuhle J and  Benkert P and  Ruprecht K and  Pawlitzki M and  Ziemssen T.},
  year = {2026},
  journal = {J Neurol},
  doi = {10.1007/s00415-026-13986-9},
  url = {https://doi.org/10.1007/s00415-026-13986-9}
}

RIS

TY  - JOUR
TI  - From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.
AU  - Inojosa H
AU  -  Masanneck L
AU  -  Akgün K
AU  -  Hagler R
AU  -  Meuth SG
AU  -  Otto C
AU  -  Schindler P
AU  -  Schulze-Bosse K
AU  -  Kuhle J
AU  -  Benkert P
AU  -  Ruprecht K
AU  -  Pawlitzki M
AU  -  Ziemssen T.
PY  - 2026
JO  - J Neurol
DO  - 10.1007/s00415-026-13986-9
UR  - https://doi.org/10.1007/s00415-026-13986-9
ER  -

APA

H, I., L, M., K, A., R, H., SG, M., C, O., P, S., K, S., J, K., P, B., K, R., M, P., & T., Z. (2026). From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.. J Neurol. https://doi.org/10.1007/s00415-026-13986-9

Source records

europe-pmc · retrieved 2026-09-27T15:02:54.698Z